LIVER INT 润色咨询

LIVER INTERNATIONAL

出版年份:2003 年文章数:2252 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:4.3% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2022-11-16 ms6000001546419962

    偏重的研究方向:细胞生物
    经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2020-09-07 ms4000000689346681

    审稿速度:2.0
    经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-10-15 YJJJJJ

    9-7 提交
    10-10 拒稿
    第一个审稿人完全否定
    第二个审稿人列出了大量的建议
    副主编也给出了一条建议
    总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投.

    6

    展开6条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2022-06-29 Dr.???

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享:目前影响因子8.76分了,非常不错,希望明年到十分

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2022-05-21 peach_adore

    mark

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2022-02-11 zhiyinghe2012

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-12-29 MS68862005

    选刊的流程是什么?

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-12-28 小动量

    期刊分类很多,如何选择合适的期刊?

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-04-03 ms5000000232033363

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2100847, encodeId=832d210084eb3, content=偏重的研究方向:细胞生物<br>经验分享:想问一下各位大佬,这个期刊接受纯机制研究吗?没有临床数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=147b8421017, createdName=ms6000001546419962, createdTime=Wed Nov 16 10:49:05 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883390, encodeId=e4d588339088, content=审稿速度:2.0<br>经验分享:跟楼上一个哥们挺像,综述投了一个半月 ,拒稿啦,附带了2个审稿人的修改意见,也是夸赞了写的不错,但就是存在几个问题,我不懂这是委婉的表达呢?还是我还有机会? 毕竟没有被指出语言方面的问题,就是需要更加丰富一下我的内容,于是我在师姐的鼓励下,准备改一改重新再投回去了,后续结果是什么就一切随缘吧,要是我成功上岸,再来跟大家分享经验,指明大家前行之路。。要是我又一次被拒了,我还是会回来跟大家分享的。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=147, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201001/0f0b8115c25146418e60df81d9142874/0c9f356181d64649945c2eee1a27f003.jpg, createdBy=964a5416426, createdName=ms4000000689346681, createdTime=Mon Sep 07 19:48:09 CST 2020, time=2020-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060724, encodeId=6c7a1060e248c, content=9-7 提交<br>10-10 拒稿<br>第一个审稿人完全否定<br>第二个审稿人列出了大量的建议<br>副主编也给出了一条建议<br>总的来说不需要审稿费,审稿也比较快,建议比较中肯,还是会愿意投., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d21b5560214, createdName=YJJJJJ, createdTime=Fri Oct 15 13:11:15 CST 2021, time=2021-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229352, encodeId=dbaf12293524b, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:目前影响因子8.76分了,非常不错,希望明年到十分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Wed Jun 29 08:31:26 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221459, encodeId=1b251221459eb, content=mark, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200806/084a1fc92a044bc49a2f018db2b60b9d/e9eb8f6f5c374213895e9be5cfdc9022.jpg, createdBy=48191511589, createdName=peach_adore, createdTime=Sat May 21 21:26:45 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192137, encodeId=70f4119213e9f, content=,, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02442867842, createdName=zhiyinghe2012, createdTime=Fri Feb 11 01:08:21 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098822, encodeId=8b781098822f8, content=选刊的流程是什么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Wed Dec 29 14:52:50 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1098821, encodeId=ed96109882123, content=期刊分类很多,如何选择合适的期刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953674, encodeId=e0e89536e488, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:投稿3天直接拒稿,效率高,投稿系统友好,但不容易中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=577f5476606, createdName=ms5000000232033363, createdTime=Sat Apr 03 22:25:24 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880833, encodeId=380688083385, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0c32045478, createdName=Dr.???, createdTime=Sun Aug 30 10:21:34 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2020-08-30 Dr.???

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享:中科院大类一区TOP期刊,一篇临床回顾性文章,2020-03-18日投稿,2020-05-07日收到一审意见,major revision,2个审稿人,第一个审稿人意见比较多,对研究方法到数据都提了不少问题。第二个审稿人基本上没有什么问题,几个单词写作的小问题。2020-05-17修回,2020-06-09返回意见,reject with hope,因为第一个审稿人有两个问题回答不好,让继续作出解释,第二个审稿人同意接受。并且这次加了一个统计学编辑审查文查,再次提了不少统计学问题。找统计学老师一起再次仔细修改后于2020-08-22修回,2020-08-29接受。整个给我的感觉就是杂志审稿非常规范、严格,希望杂志分数越来越高。

    2

    展开2条回复
共109条页码: 2/11页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分